Kiniksa PharmaceuticalsKNSA
13F holders, Q2 2024 (June 30)5holders −149
0new positions
41sold out
$18.66avg. 13F price*
At the end of Q2 2024, 5 institutions reported holding Kiniksa Pharmaceuticals Ltd. (KNSA) in their 13F filings, down 149 from Q1 2024. 0 opened new positions and 41 sold out. The largest holders were Barclays PLC ($650K), Birchview Capital, LP ($560K) and Adirondack Trust Co. ($16K).
- Company
- Kiniksa Pharmaceuticals Ltd.
- CUSIP
- G5269C101
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 41 | $100.0M |
All 13F filers, Q1 2024 → Q2 2024: 834 shares bought and 5,084,083 shares sold, net −5,083,249 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Barclays PLC | 0.00% | Reduce -17.3% | 34,839 | $650K |
| Birchview Capital, LP | 0.52% | No change | 30,000 | $560K |
| Adirondack Trust Co. | 0.01% | No change | 875 | $16K |
| Osaic Holdings, Inc. | 0.00% | Add +523.0% | 623 | $12K |
| Cwm, LLC | 0.00% | Add +222.1% | 451 | $8K |
"% of holder's portfolio" is KNSA's weight in each manager's 13F, not the share of Kiniksa Pharmaceuticals Ltd. the manager owns.